MusclePharm Corp – Separation Agreement and General Release (May 1st, 2017)
THIS SEPARATION AGREEMENT AND GENERAL RELEASE (the "Agreement") is made and entered into as of March 23, 2017 (the "Effective Date") by and between Brent Baker, an individual ("Executive"), and MusclePharm Corporation, a Nevada corporation (the "Company"). The Company and Executive are collectively referred to herein as the "parties."
MusclePharm Corp – The Securities Represented Hereby Have Not Been Registered Under the Securities Act of 1933, and Have Been Acquired for Investment and Not With a View To, or in Connection With, the Sale or Distribution Thereof. No Such Sale or Distribution May Be Effected Without an Effective Registration Statement Related Thereto or an Opinion of Counsel in a Form Satisfactory to the Company That Such Registration Is Not Required Under the Securities Act of 1933. (March 15th, 2017)
THIS NOTE AND ALL PAYMENT OBLIGATIONS HEREUNDER ARE SUBORDINATE TO THE OBLIGATIONS OF THE COMPANY TO ANB BANK, AS AND TO THE EXTENT SET FORTH IN THE SUBORDINATION AGREEMENT OF EVEN DATE HEREWITH BY AND AMONG THE COMPANY, THE HOLDER, AND ANB BANK, PROVIDED THAT NO SUCH SUBORDINATION SHALL IMPAIR, LIMIT, OR OTHERWISE ADVERSELY AFFECT THE RIGHTS OF THE HOLDER TO CONVERSION AS SET FORTH HEREIN.
MusclePharm Corp – First Amendment to Convertible Secured Promissory Note (March 15th, 2017)
This First Amendment to the Convertible Secured Promissory Note dated December 7, 2015 (the "First Amendment") is made as of January 14, 2017 (the "First Amendment Effective Date"), by and between MusclePharm Corporation (the "Company") and Ryan Drexler (the "Holder").
MusclePharm Corp – November 4, 2016 (December 2nd, 2016)
We are pleased to offer you the position of Chief Financial Officer ("CFO"). Your annual compensation will be $300,000 paid on the standard pay cycle of the company. As a CFO, you will be a part of the bonus program with a yearly bonus potential of $100,000 based on the achievement on mutually agreeable objectives to be determined between you and your supervisor. As CFO, at this time, you will report to Ryan Drexler, the Executive Chairman of the Board and Interim CEO/President.
MusclePharm Corp – Settlement Agreement (November 9th, 2016)
WHEREAS, Capstone and MusclePharm entered into the Manufacturing Agreement on November 27, 2013 and the First Amendment to the Manufacturing Agreement ("First Amendment," and collectively with the Manufacturing Agreement, the "Contract") on March 2, 2015;
MusclePharm Corp – Warrant (November 9th, 2016)
THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR REGISTERED OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS PERMITTED HEREUNDER AND IF PERMITTED UNLESS (I) A REGISTRATION STATEMENT COVERING SUCH SECURITIES IS EFFECTIVE UNDER THE ACT AND IS REGISTERED OR QUALIFIED UNDER APPLICABLE STATE AND FOREIGN LAW OR (II) THE TRANSACTION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS UNDER THE ACT AND THE REGISTRATION OR QUALIFICATION REQUIREMENTS UNDER APPLICABLE STATE AND FOREIGN LAW.
MusclePharm Corp – Convertible Secured Promissory Note (November 9th, 2016)
This Note is secured by a lien on and security interest in all of the assets and properties of the Company, as described in the Amended and Restated Security Agreement of even date herewith by and between the Company and the Holder (the "Security Agreement").
MusclePharm Corp – Amended and Restated Security Agreement (November 9th, 2016)
This Amended and Restated Security Agreement (this "Agreement"), dated as of November 8, 2016, is entered into between Ryan Drexler, an individual ("Grantee"), and MusclePharm Corporation, a Nevada corporation, as grantor ("Grantor").
MusclePharm Corp – Between MusclePharm Corporation and BioZone Holdings, Inc. And Biozone Laboratories, Inc. Dated as of April 21, 2016 (April 27th, 2016)
1 PURCHASE OF BIOZONE SHARES 1 1.1 Sale of Stock. 1 1.2 Instruments of Conveyance. 1 1.3 Consideration. 1 1.4 Payment of Purchase Price. 1 1.5 Guaranty. 4 2 TARGET PRICE ADJUSTMENTS 4 2.1 Net Working Capital Adjustment 4 2.2 Deferred Maintenance and Missing Equipment 6 2.3 Equipment Buyout Adjustment 6 3 THE CLOSING 6 3.1 Closing. 6 3.2 Payment of Closing Payment. 7 3.3 Transfer of BioZone Shares. 7 3.4 Gel Pack Purchase Order. 7 3.5 Accounts Payable Payment. 7 4 REPRESENTATIONS AND WARRANTIES OF THE SHAREHOLDER AND COMPANY 7 4.1 Organization and Qualification of Company. 7 4.2 Subsidiaries; Names; Capital Stock; Officers and Directors 8 4.3 Authority of the Shareholder. 8 4
MusclePharm Corp – Executive Employment Agreement (February 16th, 2016)
This EXECUTIVE EMPLOYMENT AGREEMENT ("Agreement") is made and entered into as of the 11th day of February 2016, by and between MusclePharm Corporation, a Nevada corporation headquartered at 4721 Ironton Street, Building A, Denver, Colorado 80239 ("Company") and Ryan Drexler ("Executive"). As used herein, the "Effective Date" of this Agreement shall mean February 10, 2016.